Dickinson Andrew D, an insider at Gilead Sciences Inc (GILD), executed a significant sale of 156,503 shares on December 9, 2025, at a price of $121.34 per share, totaling approximately $18.99 million. Following this transaction, Dickinson retains 156,503 shares in the company.
Gilead Sciences, headquartered in Foster City, California, is a biopharmaceutical company focused on the research, development, and commercialization of medicines addressing unmet medical needs. The firm employs 17,600 people and operates in over 35 countries, with a portfolio that includes treatments for HIV, viral hepatitis, COVID-19, cancer, and inflammation.
As of December 11, 2025, Gilead's market capitalization stands at $153.1 billion, with a trailing P/E ratio of 18.87 and an EPS of 6.43. The company is also anticipating earnings on April 22, 2026, with an estimated EPS of $2.09 and revenue of $7.2 billion, followed by another report on August 5, 2026, projecting an EPS of $2.27 and revenue of $7.6 billion.
Insider selling can occur for a variety of reasons, including diversification and personal financial needs. While such transactions warrant attention, they do not inherently signal negative sentiment toward the company. Investors are encouraged to consider insider activity in the context of broader market and company performance rather than in isolation.